See what’s new.
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.
Isolere Bio: Inside the journey of a Duke biotech start-up
From an invention in 1999, to start-up creation in 2017, to acquisition in 2023, learn of the twists and turns of Duke start-up Isolere Bio from its co-founders.
Sparta Biomedical, Dr. Wiley highlighted by WXII 12 News
Professor of Chemistry Dr. Benjamin Wiley was interviewed recently by Winston-Salem TV station WXII 12 News about the synthetic cartilage his lab developed.
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Radius Health, with its eventual partner Stemline Therapeutics/Menarini Group, licensed the cancer indications for this drug in 2017 out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).
PranaQ Secures $3M in Seed Funding
This post first appeared on the PranaQ website. PranaQ, a healthcare technology startup, successfully completed $3M in Seed round funding raising. The round was participated by multiple global venture capital firms, including DSC Investment, Smilegate Investment,…
Invented at Duke 2022 brings together the university research, innovation, and entrepreneurship community
Members of the Duke research, innovation, and entrepreneurship community gathered for the annual celebration of inventions and inventors, as well as to network with each other and various internal and external partners.
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Radius first licensed the indication for this drug discovered out of the Donald McDonnell lab from Duke in 2017.
HOW FAST ARE YOU AGING?
Psychologists Terrie Moffitt and Avshalom Caspi develop a measure for your rate of aging By Duke Today Staff Five decades ago, Duke psychologists Terrie Moffitt and Avshalom Caspi began working with a long-term study of…
Xilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs
National public-private consortium aims to bring together researchers, oncologists, knowledge institutes and the business community to collaboratively develop better and affordable cancer medicines more quickly DURHAM, N.C., May 3, 2022–(BUSINESS WIRE)–Xilis, Inc., a pioneering company…